OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
Launched by OTONOMY, INC. · Oct 14, 2019
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has audiometrically-defined normal hearing or up to moderately severe hearing impairment.
- • Subject has self-reported difficulty hearing in noisy environments for at least 6 months prior to Screening.
- • Subject exhibited a speech-in-noise hearing deficit in at least one ear.
- Exclusion Criteria:
- • Subject is pregnant or lactating.
- • Subject has the following hearing disorders or any other hearing disorders that may impact the efficacy assessments or safety of the subject in the opinion of the Investigator: Meniere's disease, congenital hearing loss, or genetic sensorineural hearing loss.
- • Subject has a cochlear implant or consistently uses a hearing aid.
- • Subject has worked at least 5 years as a professional musician or has had at least 15 years of formal musical training.
- • Subject self-reports bothersome, subjective tinnitus and is consistently aware of their tinnitus throughout much of the waking day.
About Otonomy, Inc.
Otonomy, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of ear disorders. With a commitment to advancing patient care, Otonomy leverages its proprietary drug delivery technologies to address unmet medical needs in conditions such as hearing loss and chronic ear diseases. The company's robust pipeline includes both clinical and preclinical programs aimed at providing effective and long-lasting treatment options. Otonomy is dedicated to improving the lives of patients through scientific excellence and a patient-centered approach to drug development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Winston Salem, North Carolina, United States
Hollywood, Florida, United States
Salt Lake City, Utah, United States
Colorado Springs, Colorado, United States
Miami, Florida, United States
Louisville, Kentucky, United States
Norfolk, Virginia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials